VGX Pharmaceuticals and Dowpharma Sign Research and Development Agreement for VGX's Lead Cancer Compound
VGX Pharmaceuticals has discovered that specific viral proteins can induce selective apoptosis in rapidly dividing cancer cells without affecting normal cells. Preclinical studies have found that VGX-100, a recombinant Viral protein r (Vpr), induces tumor death through apoptosis in a variety of established human tumor cells derived from the breast, prostate, brain, and other sources. The initial clinical studies will target individuals with Non-Hodgkin's Lymphoma.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.